Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Biorxiv : the Preprint Server for Biology|March 11, 2024
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccinationJordan Clark, Irene Hoxie, Daniel C Adelsberg, et al.
Frontiers in Immunology|April 1, 2025
Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal modelsIrene González-Domínguez, Adam Abdeljawad, Tsoi Ying Lai, et al.
Mbio|September 21, 2021
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in PigsJesús Horacio Lara-Puente, Juan Manuel Carreño, Weina Sun, et al.
Science Translational Medicine|February 15, 2023
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccinationJuan Manuel Carreño, Ariel Raskin, Gagandeep Singh, et al.
Nature Communications|October 28, 2021
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responsesWeina Sun, Yonghong Liu, Fatima Amanat, et al.
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Vaccine|June 30, 2026
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adultsSean T H Liu, Irene González-Domínguez, Amparo Martínez-Pérez, et al.
Frontiers in Immunology|June 14, 2024
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individualsAlejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval, et al.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
Pageof 8